MENY

Gällande vårdprogram äggstockscancer

Fastställd av Regionala cancercentrum i samverkan 2015-06-04

18. Förslag på fördjupningslitteratur

Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation.  J Clin Oncol. 2014 Jun 10;32(17):1840-50.

Arden-Close E, Gidron Y, Moss-Morris R. Psychological distress and its correlates in ovarian cancer: a systematic review. Psychooncology. 2008 Nov;17(11):1061-72.

Bloom JR, Petersen DM, Kang SH. Multi-dimensional quality of life among long-term (5 years) adult cancer survivors. Psychooncology 2007;16:691–706.

Fitch M I. Psychosocial management of patients with recurrent ovarian cancer: treating the whole patient to improve quality of live. Semin Oncol Nurs. 2003;19(3Suppl 1):40-53

Fitch MI, Turner F. Ovarian cancer. Can Nurse 2006;102:16-20

Hersch J, Juraskova I, Price M, Mullan B. Psychosocial interventions and quality of life in gynaecological cancer patients: a systematic review. Psychooncology. 2009 Aug;18(8):795-810.

Lammers SE, Schaefer KM, Ladd EC, Echenberg R. Caring for woman living with ovarian cancer: Recommendations for advanced practice nurses. J Obstet Gynecol Neonatal Nurs 2000;29:567-573.

Vivar CG, Canga N, Canga AD, Arantzamendi M. The psychosocial impact of recurrence on cancer survivors and family members: a narrative review.  J Adv Nurs 2009;65:724-736.

www.cancercentrum.se/sv/Vardprogram/Rehabilitering/

Börjeson S, Hursti TJ, Peterson C, Fredikson M, Fürst CJ, Avall-Lundqvist E, et al. Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale. Cancer Nurs. 1997 Aug;20(4):260-6.

Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2008 Jan;5(1):32-43.

Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18(2):163-73.

Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HHet al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007 Sep;15(9):1023-33.

Patientbroschyr, Illamående och kräkningar vid cancersjukdom och behandling, utarbetad av Evidensgruppen vid verksamhetsområde onkologi, Sahlgrenska Universitetssjukhuset Göteborg, 1 september 2011.

Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JWet al. Antiemetic drugs in oncology:pharmalogy and individulazion by pharmacogenetics. Int J Pharm. 2011 Feb;33(1):33-43.

Roila F, Warr D, Clark-Snow RA, Tonato M, Gralla RJ, Einhorn LHet al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005 Feb;13(2):104-8.

Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer.Crit Rev Oncol Hematol. 2008 Jun;66(3):218-28.

Argyriou AA, Zolota V, Kyriakopoulou O, Kalofonos HP.Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents.J BUON. 2010 Jul-Sep;15(3):435-46.

Binner M, Ross D, Browner I. Chemotherapy-induced peripheral neuropathy: assessment of oncology nurses' knowledge and practice.Oncol Nurs Forum. 2011 Jul; 38 (4):448-54.

Pachman DR, Barton DL, Watson JC, Loprinzi CL.Chemotherapy-induced peripheral neuropathy: prevention and treatment.Clin Pharmacol Ther. 2011 Sep;90(3):377-87.

Paice JA. Clinical challenges: chemotherapy-induced peripheral neuropathy.Semin Oncol Nurs. 2009 May;25(2 Suppl 1):S8-19.

Park SB et al Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.Curr Med Chem. 2008;15(29):3081-94.

Ezzo J, Richardson MA, Vickers A, Allen C, Dibble S, Issell BF, Lao L, PearlM, Ramirez G, Roscoe JA, Shen J, Shivnan JC, Streitberger K, Treish I, Zhang G. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Databaseof Systematic Reviews 2006, Issue 2. Art. No.: CD002285. DOI: 10.1002/14651858.CD002285.pub2.

Borsellino M, Young MM.Anticipatory coping: taking control of hair loss.Clin J Oncol Nurs. 2011 Jun 1;15(3):311-5.

Dougherty L. Using nursing diagnoses in prevention and management of chemotherapy-induced alopecia in the cancer patient.Int J Nurs Terminol Classif 2007 Oct-Dec;18(4):142-9

Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome – a frequent secondary manifestation in antineoplastic chemotherapy.Eur J Dermatol. 2006 Sep-Oct;16(5):494-9.

Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G.Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).Ann Oncol. 2007 Jul;18(7):1159-64.

Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre.Eur J Oncol Nurs. 2007 Jul;11(3):238-46.

Ahles TA, Saykin AJ.Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007 Mar;7(3):192-201.

Myers JS, Sousa VD, Donovan HS. Predictors of self-reported memory problems in patients with ovarian cancer who have received chemotherapy. Oncol Nurs Forum. 2010 Sep;37(5):596-603